We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Interferon-alpha treatment of four patients with the Churg-Strauss syndrome.
Annals of Internal Medicine 1998 September 2
BACKGROUND: Interferon-alpha is reported to have a beneficial effect on patients with the idiopathic hypereosinophilic syndrome.
OBJECTIVE: To study the effect of interferon-alpha on the Churg-Strauss syndrome.
DESIGN: Case series.
SETTING: University hospital.
PATIENTS: Four patients with biopsy-proven Churg-Strauss syndrome.
INTERVENTION: Interferon-alpha at dosages of 7.5 to 63 million U per week.
MEASUREMENTS: Disease extent, disease activity, and blood eosinophil count in a treatment period ranging from 14 to 25 months.
RESULTS: Interferon-alpha therapy led to remission of disease and a substantial reduction of the prednisolone requirement in two patients who had attained incomplete remission with cyclophosphamide or methotrexate. The third patient's condition stabilized, and the fourth patient maintained remission. During interferon-alpha therapy, the blood eosinophil count in all patients decreased in a dose-dependent manner and paralleled the extent of clinical disease and disease activity.
CONCLUSIONS: Interferon-alpha may be an effective treatment for the Churg-Strauss syndrome. It seems to exert its effect primarily by producing a dose-dependent decrease in the blood eosinophil count.
OBJECTIVE: To study the effect of interferon-alpha on the Churg-Strauss syndrome.
DESIGN: Case series.
SETTING: University hospital.
PATIENTS: Four patients with biopsy-proven Churg-Strauss syndrome.
INTERVENTION: Interferon-alpha at dosages of 7.5 to 63 million U per week.
MEASUREMENTS: Disease extent, disease activity, and blood eosinophil count in a treatment period ranging from 14 to 25 months.
RESULTS: Interferon-alpha therapy led to remission of disease and a substantial reduction of the prednisolone requirement in two patients who had attained incomplete remission with cyclophosphamide or methotrexate. The third patient's condition stabilized, and the fourth patient maintained remission. During interferon-alpha therapy, the blood eosinophil count in all patients decreased in a dose-dependent manner and paralleled the extent of clinical disease and disease activity.
CONCLUSIONS: Interferon-alpha may be an effective treatment for the Churg-Strauss syndrome. It seems to exert its effect primarily by producing a dose-dependent decrease in the blood eosinophil count.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app